Business Wire (Mon, 31-Aug 4:05 PM ET)
TipRanks (Thu, 27-Aug 9:25 AM ET)
TriSalus Life Sciences Reports Second Quarter 2026 Results
Business Wire (Thu, 6-Aug 4:05 PM ET)
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
Business Wire (Wed, 29-Jul 4:05 PM ET)
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
Business Wire (Thu, 16-Jul 4:05 PM ET)
Globe Newswire (Tue, 23-Jun 5:45 PM ET)
Globe Newswire (Wed, 10-Jun 10:04 AM ET)
Business Wire (Wed, 10-Jun 8:00 AM ET)
TLSI INVESTOR ALERT: Holzer & Holzer, LLC Investigation of TriSalus Life Sciences, Inc.
Globe Newswire (Fri, 5-Jun 11:39 AM ET)
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Trisalus Life Sciences trades on the NASDAQ stock market under the symbol TLSI.
As of September 1, 2026, TLSI stock price climbed to $5.17 with 80,408 million shares trading.
TLSI has a beta of 2.26, meaning it tends to be more sensitive to market movements. TLSI has a correlation of 0.11 to the broad based SPY ETF.
TLSI has a market cap of $318.34 million. This is considered a Small Cap stock.
Last quarter Trisalus Life Sciences reported $11 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.05.
In the last 3 years, TLSI traded as high as $10.42 and as low as $2.20.
The top ETF exchange traded funds that TLSI belongs to (by Net Assets): IWM, VTI, VXF, IWO, VTWO.
TLSI has underperformed the market in the last year with a price return of -1.0% while the SPY ETF gained +19.3%. However, in the short term, TLSI had mixed performance relative to the market. It has outperformed in the last 3 months, returning +51.6% vs +1.0% return in SPY. But in the last 2 weeks, TLSI shares have been beat by the market, returning -1.9% compared to an SPY return of -1.4%.
TLSI support price is $4.74 and resistance is $5.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLSI shares will trade within this expected range on the day.